Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 4

1.

The evaluation of gemcitabine in resistant or relapsing multiple myeloma, phase II: a Southwest Oncology Group study.

Weick JK, Crowley JJ, Hussein MA, Moore DF, Barlogie B; Southwest Oncology Group.

Invest New Drugs. 2002 Feb;20(1):117-21.

PMID:
12003187
2.

Gemcitabine in treating patients with refractory or relapsed multiple myeloma.

Zheng H, Yang F.

Asian Pac J Cancer Prev. 2014;15(21):9291-3. Review.

3.

Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer.

Rocha Lima CM, Eckardt JR, Leong SS, Sherman CA, Perkel JA, Putman T, Safa AR, Bahadori HR, Green MR.

Semin Oncol. 1999 Oct;26(5 Suppl 16):43-50; discussion 71-2. Review.

PMID:
10585008
4.

Pharmacogenetics and pharmacoepigenetics of gemcitabine.

Candelaria M, de la Cruz-Hernández E, Pérez-Cárdenas E, Trejo-Becerril C, Gutiérrez-Hernández O, Dueñas-González A.

Med Oncol. 2010 Dec;27(4):1133-43. doi: 10.1007/s12032-009-9349-y. Epub 2009 Nov 10. Review.

PMID:
19902390

Supplemental Content

Write to the Help Desk